Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Long-Term Deferred Tax (2016)

Historic Long-Term Deferred Tax for Angiodynamics (ANGO) over the last 8 years, with Q2 2016 value amounting to $21.7 million.

  • Angiodynamics' Long-Term Deferred Tax rose 1115.44% to $21.7 million in Q2 2016 from the same period last year, while for May 2016 it was $21.7 million, marking a year-over-year increase of 1115.44%. This contributed to the annual value of $21.7 million for FY2016, which is 1115.44% up from last year.
  • According to the latest figures from Q2 2016, Angiodynamics' Long-Term Deferred Tax is $21.7 million, which was up 1115.44% from $19.8 million recorded in Q1 2016.
  • In the past 5 years, Angiodynamics' Long-Term Deferred Tax ranged from a high of $44.3 million in Q2 2012 and a low of $15256.0 during Q2 2014
  • In the last 5 years, Angiodynamics' Long-Term Deferred Tax had a median value of $18.8 million in 2013 and averaged $17.7 million.
  • In the last 5 years, Angiodynamics' Long-Term Deferred Tax crashed by 9991.53% in 2014 and then soared by 12777100.16% in 2015.
  • Angiodynamics' Long-Term Deferred Tax (Quarter) stood at $38.6 million in 2012, then plummeted by 75.37% to $9.5 million in 2013, then grew by 24.94% to $11.9 million in 2014, then surged by 68.8% to $20.0 million in 2015, then rose by 8.15% to $21.7 million in 2016.
  • Its Long-Term Deferred Tax stands at $21.7 million for Q2 2016, versus $19.8 million for Q1 2016 and $20.0 million for Q4 2015.